3-Methyladenine (3-MA)

Catalog No.S2767 Synonyms: NSC 66389

3-Methyladenine (3-MA) Chemical Structure

Molecular Weight(MW): 149.15

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 370 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • MDC-labeled vacuoles were induced by AZD2014 and inhibited by autophagy inhibitor (3-MA). SMMC-7721 cells were treated with AZD2014 or rapamycin at concentrations of 100 and 600 nM, respectively, for 48 hours in the presence or absence of 3-MA, and then stained with MDC. Cells were immediately observed under a confocal microscope. Cells in the control group were treated with DMSO. bars, 20 μm.

    Am J Cancer Res, 2015, 5(1): 125-139. 3-Methyladenine (3-MA) purchased from Selleck.

    PC-9/ER cells were treated with CX-4945 (5 mM) for 48 h in the presence or absence of 3-MA (2 mM) and Atg7 siRNA (100 nM). Cleavage of PARP-1 and caspase-3 was shown by Western blot analysis. CT: without CX-4945; CX: CX-4945; CX+G: CX-4945 + gefitinib; CX+E: CX-4945 + erlotinib.

    PLoS One, 2014, 9(12): e114000 . 3-Methyladenine (3-MA) purchased from Selleck.

  • A: The survival ratio of AML12 cells was measured after treatment with rapamycin or 3-MA; B: Western blot was used to detect the expression of LC3 and P62 in AML12 cells treated with Rapamycin or 3-MA.

    World J Gastroenterol, 2016, 22(18): 4501-4514.. 3-Methyladenine (3-MA) purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description 3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation.
Targets
Vps34 [1]
(HeLa cells)
PI3Kγ [1]
(HeLa cells)
25 μM 60 μM
In vitro

The slight preference for Vps34 prevention by 3-Methyladenine probably arises from a hydrophobic ring specific to Vps34, which encircles the 3-methyl group of 3-Methyladenine. [1] 3-Methyladenine has been reported to cause cancer cell death under both normal and starvation conditions. 3-Methyladenine could also suppress cell migration and invasion independently of its ability to inhibit autophagy, implying that 3-Methyladenine possesses functions other than autophagy suppression. 3-Methyladenine elicits caspase-dependent cell death that is independent of autophagy inhibition. Treatment with 5 mM 3-Methyladenine reduces the percentage of glucose-starved HeLa cells displaying GFP-LC3 puncta to 23%. The levels of LC3-I are increasing and the levels of LC3-II are decreasing between 12 and 48 hours in cells that are treated with 3-Methyladenine. Conversion of LC3-I to LC3-II is suppressed by 3-Methyladenine. Treatment of HeLa cells with 3-Methyladenine at 2.5 mM or 5 mM for one day does not affect cell viability, whereas treatment with 10 mM 3-Methyladenine for one day causes a 25.0% decrease in cell viability. Treatment of cells with 2.5, 5 or 10 mM 3-Methyladenine for two days causes 11.5%, 38.0% and 79.4% decrease in viability, respectively. 3-Methyladenine decreases cell viability in a time- and dose-dependent manner. 3-Methyladenine significantly shortens the duration of nocodazole-induced-prometaphase arrest. [2] Suppression of autophagy by 3-Methyladenine inhibits SU11274-induced cell death. [3] Prolonged treatment with 3-Methyladenine (up to 9 hours) induces significant LC3 I to II conversion in wild type MEFs. Prolonged treatment with 3-Methyladenine, but not wortmannin, markedly increases GFP-LC3 punctuation/aggregation. 3-Methyladenine-induced LC3 conversion and free GFP liberation are ATG7-dependent. 3-Methyladenine treatment leads to evident increase of p62 protein level. 3-Methyladenine increases the p62 level even in Atg5−/− MEFs as well as in cells with DOX-mediated deletion of ATG5. 3-Methyladenine inhibits class I and class III PI3K in different temporal patterns. 3-Methyladenine-induced LC3 I to LC3 II conversion is dramatically compromised in Tsc2−/− cells compared with wild type cells.3-Methyladenine disrupts the anti-autophagic function of mTOR complex 1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
95D NYD4fm56T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPHN41O M4rtNlJp NUX4dpB{TE2VTx?= MmLGdoVlfWOnczDndo94fGhiaX7obYJqfG:{eTDl[oZm[3Rib3[gRmROSw>? NICzUJkzPTdzNkW2NS=>
A549  MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDWbGx3O22P MYOybC=> MYPEUXNQ NEDWZ4tz\WS3Y3XzJIdzd3e2aDDpcohq[mm2b4L5JIVn\mWldDDv[kBDTE2F NIjXXpEzPTdzNkW2NS=>
95D M4PSWmFxd3C2b4Ppd{BCe3OjeR?= MWe1cW0> M4fZR|Jp M2TwbGROW09? MYTpcohq[mm2czDCSG1ENWmwZIXj[YQh[XCxcITveIlkKGOnbHyg[IVifGh? MYqyOVcyPjV4MR?=
A549  MV;BdI9xfG:|aYOgRZN{[Xl? M1\LO|VuVQ>? M4rGNFJp M4q5OGROW09? M3Xic4lvcGmkaYTzJGJFVUNvaX7keYNm\CCjcH;weI91cWNiY3XscEBl\WG2aB?= MUCyOVcyPjV4MR?=
NBL-W-S  NWXJVYRRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\MVYEydU1? M2HOU|Zp NH3DZmRmdmijbnPld{BISU6WLU[xJJRwgGmlaYT5 M3juOVI2OzJ|MkKy
NBL-W-S  NF\HPYNCeG:ydH;zbZMhSXO|YYm= M1vE[FFuVQ>? NEnlfHU3cA>? M2rZZYlv[3KnYYPld{Bk\WyuIHHwc5B1d3OrczDpcoR2[2WmIHL5JGdCVlRvNkG= NX\tWIR3OjV|MkOyNlI>
A2780cp  NHPBWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXWbnh5OW2P NH3z[HYycA>? NI\SeXZqdmO{ZXHz[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? NHLLVXAzPTN{Mk[5OC=>
A549  M{G4XWZ2dmO2aX;uJGF{e2G7 MXm1cW0> M37LN|Jp Mom1d5VxeHKnc4Pld{BUWENiaX7keYNm\CCjY3P1cZVt[XSrb36gc4YhVEN|LVnJ MUiyOVI5PTZ{OB?=
H157 M1[1WGZ2dmO2aX;uJGF{e2G7 MXy1cW0> M4nD[VJp NHLHfHZ{fXCycnXzd4V{KFOSQzDpcoR2[2WmIHHjZ5VufWyjdHnvckBw\iCOQ{OtTWk> NXvLPIFtOjV{OEW2Nlg>
MDR MmTGRZBweHSxc3nzJGF{e2G7 NVPTNWd3OTCvTR?= NY\4UHpiPmh? MVvzeJJmdme2aHXud{B1cGVicH;3[ZIhd2ZiYX70bYNidmOncjDkdpVoew>? MU[yOVAyQTdyMR?=
HT-29  MWrBdI9xfG:|aYOgRZN{[Xl? NUHaWXN5OW2P M3[2NFQ5cA>? NH7oVVFFVVOR MX7lcohidmOnczDic5J1\XqxbXniMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> M4PublI1QDR{MUW4
Microglia  NVnGXJd3SXCxcITvd4l{KEG|c3H5 NFfnNIs2dU1? M4r0[|I1cA>? MnPS[IVkemWjc3XzJIh6eG:6aXGtbY5lfWOnZDDj[YxtKGSnYYTo M{PwTFI1QDF6NkCx
A2780cp MV3BdI9xfG:|aYOgRZN{[Xl? MWqyMlVuVQ>? MmLBNYg> M4LMRoRlUDKR MXzlcohidmOnczDjbZNxdGG2aX6tbY5lfWOnZDDj[YxtKGSnYYTo NFLCZoQzPDhzN{m0Oi=>
HepG2 NEPUbmVHfW6ldHnvckBCe3OjeR?= NHHWSlQ2dU1? NIf3SFY1cA>? MVXpcoNz\WG|ZYOgTGwhemWuZXHz[S=> MkLLNlQ4OTN3OEe=
A549 NG[zR5dCeG:ydH;zbZMhSXO|YYm= NGXmdpg2dU1? NHTab441QGh? MlvU[IVkemWjc3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGxiZHXheIgh[W6mIHX4dJJme3Orb36gcIV3\Wy|IH;mJINie3Cjc3WtN{whSmWlbHnuMVEh[W6mIFzDN{1KUQ>? NUK2PGI2OjR5ME[zNFM>
U2OS MWDBdI9xfG:|aYOgRZN{[Xl? NHnLb3EyOG2P MWOyOIg> MVPpcpRmdnOrZnnld{B1cGViZ4Lve5RpKGmwaHnibZRqd25ib3[geIhmKFV{T2OgZ4VtdHNiaX7keYNm\CCkeTDEc5g> NFPo[XozPDZ|OUCxNy=>
Saos-2 NXzDdHF4SXCxcITvd4l{KEG|c3H5 M3GxO|ExdU1? NFXwNlczPGh? Mk\SbY51\W6|aX\p[ZMhfGinIHfyc5d1cCCrbnjpZol1cW:wIH;mJJRp\SCXMl;TJINmdGy|IHnu[JVk\WRiYomgSI95 MojhNlQ3OzlyMUO=
A549 NUHsdJR6SXCxcITvd4l{KEG|c3H5 NFPXUHEyOG2P NX\1O3B3PDiq MXfhZ4NmdGW{YYTld{B1cGVicnXkeYN1cW:wIH;mJINmdGxidnnhZoltcXS7IHnu[JVk\WRiYomgVHRZ MorpNlQ3OjZ5MkK=
HCT116  MY\BdI9xfG:|aYOgRZN{[Xl? NW[z[oI2PW2P M3nGV|I1cA>? MkC0[Y5p[W6lZYOgeIhmKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IHHwbYdmdmmw MVWyOFYzPjV{Mh?=
HGC-27 M4LrfGZ2dmO2aX;uJGF{e2G7 NGrpblcyOG2P MVKxbC=> MkDybY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIxwe3NiYomgVmFFODBzIH;yJG1MNTJ{ME[= Mki0NlQ1OTZ|NEm=
U2OS  MX;GeY5kfGmxbjDBd5NigQ>? NUTzbIxVOC53L{HtUS=> MYG0PIg> Ml\5bY5lfWOnczDzZYxqdm:veXPpck1qdmS3Y3XkJINmdGxidnnhZoltcXS7IHzvd5M> M{G3VFI1OzV6M{Sy
MG-63 NVe2fI91TnWwY4Tpc44hSXO|YYm= M4\P[lAvPS9zbV2= MoXNOFhp MV7pcoR2[2W|IIPhcIlvd227Y3nuMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> M3zEUlI1OzV6M{Sy
MG-63 MUjBdI9xfG:|aYOgRZN{[Xl? MV6wMlUwOW2P NWrLdYlvOzKq MVXlcohidmOnczDzZYxqdm:veXPpck1qdmS3Y3XkJINmdGxiYYDvdJRwe2m| NE[4b3EzPDN3OEO0Ni=>
MG-63 MYnBdI9xfG:|aYOgRZN{[Xl? Mlu1NVBuVQ>? NVjrd3d7OTKq NGm1[|JmdmijbnPld{BFWC2rbnT1Z4VlKGGyb4D0c5Nqew>? MX2yOFM2QDNyMR?=
NTUB1 M3PT[2Fxd3C2b4Ppd{BCe3OjeR?= MYO1cW0> Mnu0NU42cA>? NX;DVWl[eG:2ZX70bYF1\XNiY3Xs[YNwgGmkLXnu[JVk\WRiYYDvdJRwe2m| MXOyOFM1QTF5Nh?=
T24 MXrBdI9xfG:|aYOgRZN{[Xl? NEPyN2w2dU1? NV\1Rmd2OS53aB?= NVfpOo9ZeG:2ZX70bYF1\XNiY3Xs[YNwgGmkLXnu[JVk\WRiYYDvdJRwe2m| NVfqfIF{OjR|NEmxO|Y>
SGC-7901  NFK3Z4xCeG:ydH;zbZMhSXO|YYm= NEjoWpYzdU1? NHn5cnoycA>? NH3pSmlqdmO{ZXHz[ZMhS0FvNDDpcoR2[2WmIHHwc5B1d3Orcx?= MmHlNlQ{OjF|NEC=
SMMC-7721 NXvZTJRHSXCxcITvd4l{KEG|c3H5 MUOycW0> Mn36NYg> M37HWolv[3KnYYPld{BESS12IHnu[JVk\WRiYYDvdJRwe2m| NGDwXmYzPDN{MUO0NC=>
ECSCs  MmLhRZBweHSxc3nzJGF{e2G7 MXmxNI1O NXrZWGs2PGh? MUXk[YNz\WG|ZYOgdoFx[W27Y3nuMZRz\WG2ZXSgZZBweHSxc3nz NGnae44zPDNzOUGwPS=>
MCF-7  MoXGSpVv[3Srb36gRZN{[Xl? MnL3NVBuVQ>? NVLrcnhQOjSq MVjpcohq[mm2czD0bIUh[XW2b4DoZYd6KGmwZIXj[YQh[nliY3jlcY91cGW{YYD5JIRzfWe| NIjBRpozPDNzNUW3PC=>
UOK257 NH7JWHlCeG:ydH;zbZMhSXO|YYm= Mk\qOY1O NUCzd4RzO2h? Mluz[Y5p[W6lZYOgdIFkdGm2YYjlcE1u\WSrYYTl[EBieG:ydH;zbZPDqA>? NHzOSlgzPDNyNU[wOC=>
ACHN-5968 Mn7ORZBweHSxc3nzJGF{e2G7 NEnC[4c2dU1? Mn\6N4g> NWjDcW06\W6qYX7j[ZMheGGlbHn0ZZhmdC2vZXTpZZRm\CCjcH;weI9{cXQEoB?= MnrZNlQ{ODV4MES=
Huh7 NFfkOYJCeG:ydH;zbZMhSXO|YYm= M3nBUVJuVQ>? MUGxNog> Mm\PSG1UVw>? NFy4RZVqdmirYnn0d{BCYkR6MEW1MYlv\HWlZXSgZ4VtdCCmZXH0bC=> NXXEZldtOjR{OUezNFA>
Hep3B M4LNcGFxd3C2b4Ppd{BCe3OjeR?= MYOycW0> MUKxNog> NGewWHVFVVOR NX3jU5FDcW6qaXLpeJMhSVqGOEC1OU1qdmS3Y3XkJINmdGxiZHXheIg> MY[yOFI6PzNyMB?=
RKO NUn6cYVpTnWwY4Tpc44hSXO|YYm= MXeycW0> M4PCOFFp NVXZeph6TE2VTx?= M3[1[4VvcGGwY3XzJINmdGxiZHXheIgh[nliZ3Xs[IFv[W27Y3nu MVOyOFI6OTd5Nx?=
HepG2 E47 MU\GeY5kfGmxbjDBd5NigQ>? M{CwVlIvPW2P MVS0PIg> NHLMW5ZqdmO{ZXHz[ZMhfGinIITvfIlkcXS7IH;mJGFCNCCEU1:sJIFv\CCFQ3y0 M1jnS|I1Ojd|N{O4
LoVo  NIewenNCeG:ydH;zbZMhSXO|YYm= M3\kOVVuVQ>? MnG5OFhp NEL2VHhmdmijbnPld{BFS0FvaX7keYNm\CCjcH;weI9{cXNw NYTNeGViOjR{MEG4NVI>
WiDr NVrmfoVnTnWwY4Tpc44hSXO|YYm= NWDJT21vOTCvTR?= NYjPbVNNOWh? MXrpcohq[mm2czDQR2JNNWmwZIXj[YQhVEN|IFnJJIV5eHKnc4Ppc44> MUWyOFE6ODR6OR?=
H1299  NEHsdpVHfW6ldHnvckBCe3OjeR?= NW\5Xm1mOTCvTR?= M2TDUlRp NGixfVRqdmO{ZXHz[ZMh[2m|cHzheIlvNWmwZIXj[YQh[2WubDDk[YF1cA>? MV:yOFE4OzJyOB?=
H460 MUfGeY5kfGmxbjDBd5NigQ>? M{L3cFExdU1? MVW0bC=> NYn1OnY4cW6lcnXhd4V{KGOrc4DsZZRqdi2rbnT1Z4VlKGOnbHyg[IVifGh? NFzSfnMzPDF5M{KwPC=>
A549 MoPCSpVv[3Srb36gRZN{[Xl? MV[xNI1O M3rIeVRp NHfZW|JqdmirYnn0d{BifXSxcHjh[5khcW6mdXPl[EBjgSCrcoLh[IlifGmxbh?= NGDGTnAzPDF2MkezOS=>
Hep3B M3PoTmFxd3C2b4Ppd{BCe3OjeR?= NFT0bIc2dU1? NIe3WGMzPGh? M2jZTYF1fGWwdXH0[ZMhXE6ILd8xJJBzd3SnY4Tpc44h[WejaX7zeEB{\XK3bTDzeIFzfmG2aX;uMY1m\GmjdHXkJIFxd3C2b4Ppdy=> NUDqbHpKOjRyNk[2PVM>
SMMC-7721 MknVRZBweHSxc3nzJGF{e2G7 NFrEdoQ2dU1? MYCyOIg> MkD4ZZR1\W63YYTld{BVVkZvzsGgdJJwfGWldHnvckBi\2GrboP0JJNmenWvIIP0ZZJ3[XSrb36tcYVlcWG2ZXSgZZBweHSxc3nz MlvmNlQxPjZ4OUO=
HO8910 MVnBdI9xfG:|aYOgRZN{[Xl? NIr2RosyOG2P NI\5PJoyOmh? NVfHV4Zb\W6qYX7j[ZMhSjF7LXnu[JVk\WRiYYDvdJRwe2l? NUHsVJpTOjN7OEO2NVA>
MCF7 Ml3pSpVv[3Srb36gRZN{[Xl? Mn\rOY1O MnTlNlRp MXTpcoNz\WG|ZYOgR5VQKGmwZIXj[YQh[2WubDDk[YF1cA>? NIXHdoszOzl4Mk[yPS=>
HONE-1  NXXYc|cxTnWwY4Tpc44hSXO|YYm= NIi5WmY2dU1? MkPnNYg> NHvSPYdz\XC{ZYPz[ZMhPnJvbXXkbYF1\WRiUl;TJJBzd2S3Y4Tpc44> NV7VPVM3OjN6OUKzOVg>
HeLa M17VemZ2dmO2aX;uJGF{e2G7 NYLWPWJIOTCvTR?= MoLrNog> MXnzeZBxemW|c3XzJGxEOyCLSTDlfJBz\XO|aYPvci=> MYKyN|g3PDd|OB?=
HepG2 MV;GeY5kfGmxbjDBd5NigQ>? Mn6yNVBuVQ>? MnvGNlRp MXrpcohq[mm2czDzbXRKT0GULTDhcoQhUEKVUz3pcoR2[2WmIHH1eI9xcGGpeR?= MVGyN|gyPzB2MB?=
SH-SY5Y MVrGeY5kfGmxbjDBd5NigQ>? NXTkfGw1OW2P NGKyWpgzPGh? NGDlO|ZqdmirYnn0d{B1cGViYYX0c5Bp[We7IHnu[JVk\WRiYomgWG9EWA>? Mo[5NlM4PDNzNEi=
SH-SY5Y NVP3b|ZkSXCxcITvd4l{KEG|c3H5 NGfRT3I2dU1? NEjEVJUycA>? M4O5OYFjd2yrc3jld{Bk\Wyjc4Tyc4whdmW3cn;wdo91\WO2aY\lJIVn\mWldB?= M{fvO|I{PjF7M{m1
PC12  MYfGeY5kfGmxbjDBd5NigQ>? MWKxNI1O MUSyOIg> NVezXmx3f2G2ZYK= M1XjOuKhcW6qaXLpeJMh[2i7bX;0dplxe2mwLXzpb4UheHKxdHXhd49u[WxiYXP0bZZqfHlw MlvhNlM3ODN7N{m=
OV2008 NFXwXG9CeG:ydH;zbZMhSXO|YYm= MVK1cW0> NVjlV|R2OjSq M33jbINwdn[ncoTzJGZVYTd{MDD3bZRpKEOGRGCgbY51dyCjbjDh[IRqfGm4ZTDl[oZm[3RidH;3ZZJleyCtaXzsbY5oKG:4YYLpZY4h[2GwY3XyJINmdGy| M{Lp[VI{PTl{Mkix
A2780 NH3RcXFCeG:ydH;zbZMhSXO|YYm= M37zbVVuVQ>? MYqyOIg> NGDET2Jkd264ZYL0d{BHXFl5MkCge4l1cCCFRFTQJIlvfG9iYX6gZYRlcXSrdnWg[YZn\WO2IITve4Fz\HNia3nscIlv\yCxdnHybYFvKGOjbnPldkBk\Wyucx?= MnfRNlM2QTJ{OEG=
Saos-2  MXXBdI9xfG:|aYOgRZN{[Xl? M{PtXVFuVQ>? MV:5Oog> MUfpcoNz\WG|ZYOgZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KFCFWB?= MkPPNlM2PjNzN{G=
1321N1 NFLyWI9EgXSxdH;4bYNqfHliQYPzZZk> MlPEOY1O NX:3Tml3OjSq MXTwdo91\WO2czDj[YxtKGGpYXnud5QhWEOQLXnu[JVk\WRidH;4bYNqfHl? NUjKcYh1OjN3MkWyOlU>
SH-SY5Y NUXBeGtlS3m2b4TvfIlkcXS7IFHzd4F6 MlPIOY1O NE\qNmYzPGh? NFXSc3pqdmO{ZXHz[ZMhWEOQIITvfIlkcXS7 NYi3UIUyOjN3MkWyOlU>
HT-29  NVnsToVqTnWwY4Tpc44hSXO|YYm= NFq0[pAydU1? M3fwdVQ5Nzl4aB?= M1f2XYlvcGmkaYTzJGFOWEtiaX7keYNmeyCjdYTvdIhi\2mlIHPlcIwh\GWjdHi= NFv3cGQzOzVyOEK3Ni=>
OR6 M1XQ[mZ2dmO2aX;uJGF{e2G7 MYSxNI1O NYXX[4M{PzKq M4XpWJN2eHC{ZYPz[ZMhUEOYIILldIxq[2G2aX;uJIFv\CCob4LtZZRqd25ib3[gZZV1d3CqYXfvd49u\XN? MYGyN|M6PTh5NR?=
Hela  M3[0W2Z2dmO2aX;uJGF{e2G7 NUDYeI1lPW2P M1vHNVI1cA>? NGjL[|RqdmirYnn0d{B{fGG{dnH0bY9vNWmwZIXj[YQh[XW2b4DoZYd6 NWLnZ4ViOjN|OUW2O|k>
MCF-7  MWnGeY5kfGmxbjDBd5NigQ>? NYHZZ4tlPW2P M3jwSVI1cA>? M17lfYlvcGmkaYTzJJN1[XK4YYTpc44ucW6mdXPl[EBifXSxcHjh[5k> NXG1b212OjN|OUW2O|k>
HUVECs MkDTSpVv[3Srb36gRZN{[Xl? MmXjN41O NULMXJE1OjSq MUPicI9kc3NidHjlJJBzd3SnY4TpeoUh\W[oZXP0JI9nKHKnc4\ldoF1em:uIHL5JIlvcGmkaYTpcoch[XW2b4DoZYd6 MkOzNlM{PTh7Mki=
T24 NW[xbG1qTnWwY4Tpc44hSXO|YYm= MYmxNI1O NVO4ZpZSOWh? MkjRdoVlfWOnczD0bIUh[2ynYY\h[4Uhd2ZiTFOzJIFnfGW{IHLhbYNidGmwIITy[YF1dWWwdB?= M4rCfVI{OzV2MEiw
U251MG  NGL4PW5HfW6ldHnvckBCe3OjeR?= MWqzcW0> MmDrNYg> Mnjzd5VxeHKnc4Pld{BNSzNvSVmgdJJwfGWrbjDlfJBz\XO|aX;u MX2yN|M{QDZzOB?=
GTL-16  MXXBdI9xfG:|aYOgRZN{[Xl? MVm1cW0> MWqyOIg> NXvPVo8{emWmdXPld{Bk\WyuII\pZYJqdGm2eTDhd{Bkd22yYYLl[EB1dyClZXzsd{B1emWjdHXkJJdqfGhiTVXUJIlvcGmkaYTvdpM> NGP2THEzOzNzM{S5NC=>
T-47D NVz2flNHTnWwY4Tpc44hSXO|YYm= M3fmbFExdU1? MUSybC=> NV6zOlFGcW6qaXLpeJMh[XW2b4DoZYd6KHC{b3Pld5Mh[W6mIHnuZ5Jm[XOnczDyZZBidXmlaX6gbY5lfWOnZDDhdI9xfG:|aYO= MoKzNlM{ODByMk[=
PaCa44 NEHqdY9CeG:ydH;zbZMhSXO|YYm= MkPPNk42dU1? M2rjZ|Fp MYHy[YR2[2W|wrDn[Y5qeGmwLX3l[IlifGWmIHHwc5B1d3Orcx?= MVGyN|EzPDFzMh?=
MDA-MB231 NIfWbnRHfW6ldHnvckBCe3OjeR?= MXi1cW0> Mn:1NYg> MUTpcoNz\WG|ZYOgdoV{fmW{YYTyc4wudWWmaXH0[YQh[2G|cHHz[UBi[3SrdnH0bY9vKGGwZDDj[YxtKGSnYYTo MmjmNlMxQDh6NUC=
HeLa MXjBdI9xfG:|aYOgRZN{[Xl? NYj3VoJoOTCvTR?= MlXGNog> NV;ZRYVW\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JINwNXS{ZXH0cYVvfCC5aYToJHBGUQ>? M{n6XlI{ODByMUO1
SK-HEP-1 M3H2OWFxd3C2b4Ppd{BCe3OjeR?= M4m0UVExdU1? NImwXGsycA>? MlL2dJJwfGWldIOgZYdicW6|dDDheZRweGijZ4mgZY5lKGmwZIXj[ZMh[XCxcITvd4l{KGmwIHL1[oFtcW5vdILlZZRm\CClZXzsdy=> M3K2XFIzQDV6NkS5
HepG2 M4TGO2Fxd3C2b4Ppd{BCe3OjeR?= M1TIR|NuVQ>? M{XaPVVp NIXJWodz\WS3Y3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgVWR{ MUmyNlg{PjV7NR?=
MCF-7  M1rxT2Z2dmO2aX;uJGF{e2G7 NHLsWIIzdU1? MVqyOIg> M1KwTIlvcGmkaYTzJIF2fG:yaHHnfUBqdmS3Y3XkJIJ6KFSPwrC= MYCyOFk4ODZ5Nh?=
MDA-MB-231 M{jOXWZ2dmO2aX;uJGF{e2G7 NFfpfoszdU1? NF3aSHUzPGh? NWL6XGxocW6qaXLpeJMh[XW2b4DoZYd6KGmwZIXj[YQh[nliVF5CpC=> NG[3NYwzPDl5ME[3Oi=>
MCF-7  MmW5SpVv[3Srb36gRZN{[Xl? NYPOZlRPOm2P NVHUdnFyPDiq NU[xOW81eHKxbX;0[ZMhXE1vaX7keYNm\CClZXzsJIRm[XSq MX6yOFk4ODZ5Nh?=
MDA-MB-231 NI\rdmNHfW6ldHnvckBCe3OjeR?= NVXucHBjOm2P MlnROFhp MWXwdo9ud3SnczDUUU1qdmS3Y3XkJINmdGxiZHXheIg> NUjubYxXOjR7N{C2O|Y>
PANC-1  Mk\zRZBweHSxc3nzJGF{e2G7 M3rRN|FuVQ>? NFG0TIs1QGh? MVnEUXNQ MVPlcohidmOnczDic5J1\XqxbXniMYlv\HWlZXSgZ4VtdCC4aXHibYxqfHlibH;zdy=> NFnRSmQzPDh2MkG1PC=>
MDA-MB 231 M3TSRmFxd3C2b4Ppd{BCe3OjeR?= M3TrdVVuVQ>? NHq3TmkxNjWq NIHCfpJud2S3bHH0[ZMhXG:lb33pcuKvyqCrbnT1Z4VlKGGyb4D0c5Nqew>? NHHjRYQzPDh|MEe4NS=>
Microglia  MnPhRZBweHSxc3nzJGF{e2G7 NHfRUHc2dU1? MY[yOIg> MnLt[IVkemWjc3XzJIh6eG:6aXGtbY5lfWOnZDDj[YxtKGSnYYTo M3n2flI1QDF6NkCx
A2780cp NFHxcYFCeG:ydH;zbZMhSXO|YYm= Mlr4Nk42dU1? NFe2[pkycA>? M2q1[oRlUDKR Morz[Y5p[W6lZYOgZ4l{eGyjdHnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NGnPflkzPDhzN{m0Oi=>
HepG2 M{nuVWZ2dmO2aX;uJGF{e2G7 NWXOUlVsPW2P MmHLOIg> MmrYbY5kemWjc3XzJINmdGy3bHHyJIxmfmWuczDv[kBJVMLi MYWyOFcyOzV6Nx?=
U2OS MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnQPWNKOTCvTR?= NIroOm4zPGh? M37KU4lvfGWwc3nmbYV{KHSqZTDndo94fGhiaX7obYJqfGmxbjDpcoR2[2WmIHL5JGRwgA>? NYSwR41NOjR4M{mwNVM>
HCT116 MoG0RZBweHSxc3nzJGF{e2G7 NX7tZ41NPW2P MkTONlRp MmPYSG1UVw>? M2LZTIVvcGGwY3XzJIFxcWenbnnuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> Ml\1NlQ3OjZ3MkK=
MCF-7  NV\pRZJESXCxcITvd4l{KEG|c3H5 MWiwMlFuVQ>? M2m4ZlZp NXXBNVZs\W6qYX7j[ZMhe2m{dHnuc4wucW6mdXPl[EBieG:ydH;zbZM> NXj1XIhqOjJ5NUG5PFk>
PC-3  M1fXWGFxd3C2b4Ppd{BCe3OjeR?= NFLsOFIzdU1? MX[ybC=> Ml;YbY5kemWjc3XzJG9TUS2rbnT1Z4VlKGOnbHyg[IVifGh? M2PxelIzPzR3NUiw
U251  M{jyUWFxd3C2b4Ppd{BCe3OjeR?= MWS1cW0> NVfnZ4NEOjSq NHS4TVBqdmO{ZXHz[ZMhWzFvaX7keYNm\CClZXzsJIRm[XSq NVnDV4ZOOjJ3N{m3PFg>
HeLa  M1PWOGFxd3C2b4Ppd{BCe3OjeR?= M{DrbVVuVQ>? M1T5[|I1cA>? MlPsbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDj[YxtKGSnYYTo M3PVcFIzPTR3MUK4
A549 NFH4NYlHfW6ldHnvckBCe3OjeR?= MnTZNE4ydU1? NF;RPI4zPGh? NEXjNYt{fXCycnXzd4V{KFOXMUGyO|QucW6mdXPl[EBk\WyuIHTlZZRp NXOxepd7OjJ2Nk[5OlA>
pDCs NUnkb2tbTnWwY4Tpc44hSXO|YYm= MUixNI1O MWmwMlVp M{\1RuKhemWmdXPld{B1cGViaX7keYN1cW:wIH;mJGlHVi4QsTDifUB{e1KQQUSw MVKyNlM6PjV7OR?=
BGC-823 NXThO3dVTnWwY4Tpc44hSXO|YYm= MYC1cW0> NYTQbHlvOmh? NUG5bolycW6qaXLpeJMhfGinIILheIUhd2ZiYYX0c5Bp[WerYzDj[Yxtew>? NXn3RW1nOjJ|MkKxOVI>
U937 NHnkUpNHfW6ldHnvckBCe3OjeR?= NYHyemVwOm2P M4HCfVEzcA>? MYfk[YNz\WG|ZYOgeIhmKGG3dH;wbIFogSC{YYTpc:Kh NVLz[FZrOjJzNUWxOVA>
Marc-145 NUjybnk{TnWwY4Tpc44hSXO|YYm= MVS1cW0> MnvBNVIwOjRxM{\o NVzFT2FMemWmdXPld{B1cGViUGLSV3YhfGm2ZYLzJIFv\CC2aHWgdJJwfGWrbjDlfJBz\XO|aX;u NYjr[5RwOjJzMUm5NFA>
HBx  NGXFZlFCeG:ydH;zbZMhSXO|YYm= MUGxNI1O MV60PIg> MXfEUXNQ Mli4bY5kemWjc3XzJINmdGxiZHXheIg> NYmyZm4zOjJyMkCwO|g>
MCF-7 MnHISpVv[3Srb36gRZN{[Xl? M3f3RVExdU1? NGmxVGs1QGh? NGe3cW5jdG:la4OgZZV1d3CqYXf5JIlv\HWlZXSgZpkh[m:{dHX6c41q[g>? NIH4PIozOTl|MUmzOy=>
RMPI8226  MlLqSpVv[3Srb36gRZN{[Xl? NGPae2Q2dU1? MmTwNYg> MmfId5VxeHKnc4Pld{B1cGVibHX2[Ywhd2ZiYYX0c5Bp[We7IIXu[IVzKG63dILp[Y51KGSncHzleIlwdg>? NGm1[oIzOTlzNU[yNC=>
PC12/TetOn MWfGeY5kfGmxbjDBd5NigQ>? NYDYe29COC5zL{HtUS=> NHLnZZgyQGh? MWfs[YFleyC2bzFOtU1{gW5qV2SpJIFk[3WvdXzheIlwdixidH;4bYNqfHluIHHu[EBwdGmpb33ldkBnd3KvYYTpc47DqA>? MXqyNVkxPjZ3OR?=
HeLa  M4W0N2N6fG:2b4jpZ4l1gSCDc4PhfS=> NIW5XZgzdU1? MVKyOIg> NFrSUGlqdmirYnn0[ZMhfGinIHP5eI91d3irY3n0fUBw\iC|aXzpZolvcW5idH:gTIVN[SClZXzsd{4> NELSe4gzOTh5NUO4OS=>
Jurkat MlL5SpVv[3Srb36gRZN{[Xl? MWmxNI1O MYmxbC=> M1f2d4Rm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBNSzNvSVmgZY5lKHSqZTDmc5Ju[XSrb36gc4Yh[XW2b4DoZYdwe2:vZYO= MVeyNVg3PDB|Nx?=
K562 MWXGeY5kfGmxbjDBd5NigQ>? NIrPblcyOG2P NYPjd2ZkOWh? MWPk[YNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gUGM{NUmLIHHu[EB1cGViZn;ycYF1cW:wIH;mJIF2fG:yaHHnc5NwdWW| MnfPNlE5PjRyM{e=
Nara-H M{XWdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUi1cW0> MVW0PIg> Mo\l[Y5p[W6lZYOgeIVue2m{b3zpcZV{dWWmaXH0[YQhe3WycILld5Nqd25ib3[gUoFz[S2KIHPlcIwheHKxbHnm[ZJifGmxbh?= MYSyNVgxPTB|Mx?=
HUVECs NXzyXZhrTnWwY4Tpc44hSXO|YYm= NHTBOJMyOG2P NGTsOXkxNjWq M1jXOYRm[3KnYYPld{B1cGViQVfFMWJUSWmwZIXj[YQh[XW2b4DoZYd6KGyndnW= NV3tSWc3OjF2Nki1PVI>
HepG2 NYOxZpRmSXCxcITvd4l{KEG|c3H5 M1raZVJuVQ>? NEPFb20ycA>? NIPyXW1mdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBk\WyuIHTlZZRp MmDUNlE1PTN4OUG=

... Click to View More Cell Line Experimental Data

In vivo 3-Methyladenine blocks autophagy through its effect on class III phosphatidylinositol 3-kinase (PI3K). 3-Methyladenine treatment does not alter the degree of hemorrhage compared with the subarachnoid hemorrhage (SAH) group. 3-Methyladenine pretreatment significantly aggravates neurological symptoms when compared with the SAH + vehicle group. Autophagy is decreased when 3-Methyladenine treatment is applied. Conversely, cleaved caspase-3 is markedly up-regulated in the SAH + 3-Methyladenine group. In line with the up-regulation of cleaved caspase-3 expression, the number of TUNEL-positive cells in the right cortex is significantly increased in the SAH + 3-Methyladenine group compared with the SAH + vehicle group. [5]

Protocol

Kinase Assay:[4]
+ Expand

Protein degradation assay:

HeLa cells are radiolabeled for 24 hours with 0.05 mCi/mL l-[U- 14C]valine. At the end of the labeling period, cells are rinsed three times with PBS. Cells are incubated for the designated times in either full medium or EBSS with or without the presence of 10 mM 3-Methyladenine.
Cell Research:[2]
+ Expand
  • Cell lines: HeLa cell line
  • Concentrations: 1-10 mM
  • Incubation Time: 24, 48 or 72 hours
  • Method: Cell (such as HeLa cell) viability is determined by a trypan blue exclusion assay. Briefly, after treated with 3-Methyladenine, both adherent and floating cells are collected and suspended in phosphate buffered saline (PBS, pH 7.4) at a final density of 1-2 × 106/mL. An equal volume of 0.4% trypan blue solution (w/v, in PBS) is added to the cell suspension and mixed thoroughly. After incubation at room temperature for 3 min, cell counting is performed using a hemacytometer.
    (Only for Reference)
Animal Research:[5]
+ Expand
  • Animal Models: Adult male Sprague–Dawley rats weighing 300-350 g
  • Formulation: Saline
  • Dosages: 400 nM
  • Administration: Intracerebral ventricular
    (Only for Reference)

Solubility (25°C)

In vitro Water 10 mg/mL (67.04 mM) warming
Ethanol 4 mg/mL (26.81 mM)
DMSO 3 mg/mL warmed (20.11 mM)
In vivo water 10mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 149.15
Formula

C6H7N5

CAS No. 5142-23-4
Storage powder
in solvent
Synonyms NSC 66389

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) supplier | purchase 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) cost | 3-Methyladenine (3-MA) manufacturer | order 3-Methyladenine (3-MA) | 3-Methyladenine (3-MA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID